David Wambeke Purchases 33,333 Shares of NeuroOne Medical Technologies (NASDAQ:NMTC) Stock

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) insider David Wambeke purchased 33,333 shares of the stock in a transaction that occurred on Thursday, August 27th. The shares were acquired at an average price of $2.01 per share, for a total transaction of $66,999.33. Following the completion of the transaction, the insider directly owned 199,999 shares of the company’s stock, valued at $401,997.99. The trade was a 20.00% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

NeuroOne Medical Technologies Stock Performance

Shares of NASDAQ NMTC opened at $1.62 on Tuesday. The stock has a market cap of $14.76 million, a PE ratio of -1.71 and a beta of 0.65. NeuroOne Medical Technologies Corporation has a 12-month low of $1.42 and a 12-month high of $6.96. The company has a 50-day moving average of $2.08 and a 200 day moving average of $3.43.

NeuroOne Medical Technologies (NASDAQ:NMTC) last released its earnings results on Thursday, August 13th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.07). The business had revenue of $1.97 million during the quarter, compared to analysts’ expectations of $2.17 million. NeuroOne Medical Technologies had a negative return on equity of 128.12% and a negative net margin of 71.50%. On average, sell-side analysts forecast that NeuroOne Medical Technologies Corporation will post -0.39 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently commented on NMTC shares. Weiss Ratings downgraded NeuroOne Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 21st. Maxim Group set a $5.00 target price on NeuroOne Medical Technologies and gave the company a “buy” rating in a report on Friday, August 14th. Finally, LADENBURG THALM/SH SH raised their target price on NeuroOne Medical Technologies from $1.60 to $8.00 and gave the stock a “buy” rating in a research note on Wednesday, May 13th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $7.33.

Institutional Trading of NeuroOne Medical Technologies

Hedge funds and other institutional investors have recently made changes to their positions in the company. Bard Associates Inc. purchased a new position in NeuroOne Medical Technologies in the second quarter worth approximately $929,000. Legato Capital Management LLC purchased a new position in shares of NeuroOne Medical Technologies during the 4th quarter worth $34,000. Susquehanna International Group LLP purchased a new stake in NeuroOne Medical Technologies in the 2nd quarter valued at about $41,000. Vanguard Group Inc. lifted its position in NeuroOne Medical Technologies by 31.2% in the third quarter. Vanguard Group Inc. now owns 1,578,237 shares of the company’s stock valued at $1,403,000 after buying an additional 375,639 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in NeuroOne Medical Technologies by 10.2% during the fourth quarter. Renaissance Technologies LLC now owns 763,028 shares of the company’s stock worth $578,000 after buying an additional 70,428 shares during the period. Institutional investors and hedge funds own 16.07% of the company’s stock.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.